Asieris(SH:688176)2026-01-30 09:00Financial Projections - The company expects a net profit attributable to shareholders of the parent company for 2025 to be between -377.67 million yuan and -453.20 million yuan, representing a year-on-year increase in losses of 18.00% to a decrease of 1.67%[3]. - The projected operating revenue for 2025 is approximately 242.48 million yuan to 290.98 million yuan, an increase of 20.30% to 44.36% compared to the previous year[3]. - The company’s total profit for 2024 was -386.80 million yuan, with a net profit attributable to shareholders of -384.06 million yuan[6]. - The company’s non-recurring gains and losses have decreased year-on-year, positively impacting the net profit attributable to shareholders[7]. - The financial data provided is preliminary and subject to final audit in the 2025 annual report[11]. Research and Development - Research and development expenses are expected to be between 253.67 million yuan and 304.40 million yuan, a decrease of 2.41% to 18.67% year-on-year[5]. - The company achieved significant progress in the development of multiple products, including APL-1702, which has been selected for presentation at the 2025 International Photodynamic Conference[7]. - APL-2302 has received approvals from both the FDA and NMPA for clinical trials, with the first subject enrolled in March 2025[8]. - The company’s APLD-2304, a portable disposable blue light bladder endoscope, has had its registration application accepted by the EU notified body, aimed at improving bladder cancer detection rates[9]. - APL-1401 for treating moderate to severe active ulcerative colitis has shown positive preliminary results in a Phase Ib clinical trial, with plans for further evaluation in a larger patient group[9].